{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:16:06Z","timestamp":1768004166644,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12894-019-0484-2","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T15:02:53Z","timestamp":1560178973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3064-7895","authenticated-orcid":false,"given":"Inkeun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Sup","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum Sik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"484_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/IJNRD.S42097","volume":"7","author":"LS Schmidt","year":"2014","unstructured":"Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis. 2014;7:253\u201360.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"484_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular Tumours. Eur Urol. 2016;70(1):93\u2013105.","journal-title":"Eur Urol"},{"issue":"5","key":"484_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","volume":"43","author":"LS Schmidt","year":"2016","unstructured":"Schmidt LS, Linehan WM. Genetic predisposition to kidney cancer. Semin Oncol. 2016;43(5):566\u201374.","journal-title":"Semin Oncol"},{"key":"484_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0959-8049(14)70131-5","volume":"50","author":"R Srinivasan","year":"2014","unstructured":"Srinivasan R, Su D, Stamatakis L, Siddiqui MM, Singer E, Shuch B, Nix J, Friend J, Hawks G, Shih J, et al. 5 mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib. Eur J Cancer. 2014;50:8.","journal-title":"Eur J Cancer"},{"issue":"22","key":"484_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"484_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","volume":"69","author":"NM Tannir","year":"2016","unstructured":"Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, et al. Everolimus versus Sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866\u201374.","journal-title":"Eur Urol"},{"issue":"3","key":"484_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","volume":"17","author":"AJ Armstrong","year":"2016","unstructured":"Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378\u201388.","journal-title":"Lancet Oncol"},{"issue":"2","key":"484_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4143\/crt.2016.584","volume":"50","author":"Ki Sun Jung","year":"2018","unstructured":"Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, Kang JH, Lee S, Rha SY, Lee KH, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study. Cancer Res Treat. 2018;50:488\u201394.","journal-title":"Cancer Research and Treatment"},{"issue":"5","key":"484_CR9","doi-asserted-by":"publisher","first-page":"e997","DOI":"10.1016\/j.clgc.2018.05.011","volume":"16","author":"I Park","year":"2018","unstructured":"Park I, Lee SH, Lee JL. A multicenter phase II trial of Axitinib in patients with recurrent or metastatic non-clear-cell renal cell carcinoma who had failed prior treatment with Temsirolimus. Clin Genitourin Cancer. 2018;16(5):e997\u2013e1002.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"484_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","volume":"374","author":"WM Linehan","year":"2016","unstructured":"Cancer Genome Atlas Research N, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135\u201345.","journal-title":"N Engl J Med"},{"issue":"1","key":"484_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/ng.3146","volume":"47","author":"S Durinck","year":"2015","unstructured":"Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015;47(1):13\u201321.","journal-title":"Nat Genet"},{"issue":"13","key":"484_CR12","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","volume":"19","author":"WM Linehan","year":"2013","unstructured":"Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19(13):3345\u201352.","journal-title":"Clin Cancer Res"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0484-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-019-0484-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-019-0484-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:13:43Z","timestamp":1591658023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-019-0484-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1186\/s12894-019-0484-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"28 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. The data do not contain any information that could identify the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}